Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Mar 2022 · 1 min read
In brief
In brief
Study examines autotaxin as a serum biomarker for detecting graft fibrosis in pediatric patients following living donor liver transplantation for biliary atresia. Correlates autotaxin levels with histological findings during routine post-transplant follow-up to assess its clinical utility in monitoring graft health.
Written by the GCMD Library team from the article.
Background
: Pediatric patients sometimes develop graft fibrosis after living donor liver transplant (LDLT). Autotaxin is a recently developed serum marker for hepatic fibrosis. We studied the relationship between serum autotaxin levels and histological findings in patients after LDLT for biliary atresia (BA). Methods: Information on patients aged